Susan Horvath - 01 Oct 2024 Form 4 Insider Report for Panbela Therapeutics, Inc. (PBLA)

Role
V.P. of Finance & CFO
Signature
/s/ Joshua L. Colburn, Attorney-in-Fact
Issuer symbol
PBLA
Transactions as of
01 Oct 2024
Net transactions value
$0
Form type
4
Filing time
03 Oct 2024, 16:26:59 UTC
Previous filing
29 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBLA Stock Option (right to buy) Award $0 +25,480 $0.000000 25,480 01 Oct 2024 Common Stock 25,480 $0.3890 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option fully vests on October 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.